Low-density lipoprotein cholesterol lowering by adding ezetimibe to statin is associated with improvement of postprandial hyperlipidemia in diabetic patients with coronary artery disease. (March 2017)

• Record Type: Journal Article
• Authors: Nakamura, Akihiro; Kajitani, Shoko; Monma, Yuto; Sato, Kenjiro; Terui, Yosuke; Kanazawa, Masanori; Noda, Kazuki; Endo, Hideaki; Takahashi, Tohru; Nozaki, Eiji
• Is Part Of: IJC metabolic & endocrine. Volume 14(2017)
• Page Start: 9
• Page End: 15
• Publication Date: 2017-03
• Subjects: Diabetes -- Ezetimibe -- Low-density lipoprotein cholesterol -- Postprandial hyperlipidemia -- Coronary artery disease; Cardiovascular system -- Pathophysiology -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; 616.1
• DOI: 10.1016/j.ijcme.2016.11.001
• Languages: English
• ISSNs: 2214-7624

Abstract

Abstract: Objective and methods: We investigated the hypothesis that serum low-density lipoprotein cholesterol (LDL-C) reduction by ezetimibe is associated with the improvement in postprandial hyperlipidemia by performing an oral fat loading test before and 24 weeks after ezetimibe treatment in diabetic (n = 29) and non-diabetic (n = 30) male patients with coronary artery disease (CAD). Results: Serum LDL-C levels were significantly reduced by ezetimibe in both groups (diabetic, from 120.3 ± 39.4 to 79.5 ± 23.2 mg/dL, p < 0.001; non-diabetic, from 98.2 ± 41.7 to 76.7 ± 29.2 mg/dL, p < 0.001), and the mean reduction in serum LDL-C was greater in diabetic than non-diabetic patients (− 32.0 vs. − 19.0%, p = 0.004). The area under the curve (AUC) for triglyceride (TG) and remnant-like particle cholesterol (RLP-C) decreased significantly in both groups. When compared with the reduction before and after treatment in AUC of TG (∆ AUC0–6 h TG) and RLP-C (∆ AUC0–6 h RLP-C), they were significantly greater in diabetic than non-diabetic patients (∆ AUC0–6h TG, − 28.9 vs. − 12.2%, p = 0.028; ∆ AUC0–6h RLP-C, − 27.8 vs. − 12.3%, p = 0.007). In diabetic patients, ∆ AUC0–6 h TG and ∆ AUC0–6 h RLP-C in the highest tertile of serum LDL-C reduction were significantly greater than those in the lowest tertile (∆ AUC0-6h TG, − 34.1 vs. − 20.9%, p = 0.012; ∆ AUC0-6h RLP-C, − 34.5 vs. − 15.1%, p = 0.024). Conclusions: These findings suggest that serum LDL-C reduction by ezetimibe might be associated with the improvement of postprandial hyperlipidemia in diabetic patients with CAD.